Revolution Medicines Business Summary

Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for RAS-addicted cancers. The company operates primarily through a research and development business model, currently generating negligible revenue as it advances its deep pipeline toward commercialization. Its primary business segments are categorized into its RAS(ON) Inhibitors, which target the active state of RAS variants (e.g., RMC-6236/daraxonrasib and RMC-6291), and RAS Companion Inhibitors designed for combination therapies. As of early 2026, the company is focused on late-stage clinical execution, notably its Phase 3 RASolute trials in pancreatic and lung cancers. Within the competitive landscape, Revolution Medicines contends with precision oncology firms such as Relay Therapeutics, Erasca, and Mirati Therapeutics (now part of Bristol Myers Squibb), positioning itself as a leader in the "RAS(multi)" inhibitor space with a differentiated focus on tri-complex inhibitors. The company was founded by a distinguished group of academic and industry veterans, including Kevan Shokat, Michael Fischbach, and Martin Burke, whose pioneering work in chemical biology forms the basis of the company’s drug discovery platform. The executive leadership team is led by Dr. Mark A. Goldsmith, who serves as President, CEO, and Chairman of the Board. Key executives include Dr. Steve Kelsey (President, Research and Development), Jack Anders (Chief Financial Officer), Margaret Horn (Chief Operating Officer), and Dr. Alan Sandler, who joined as Chief Development Officer in late 2025. The company is backed by prominent institutional investors, including Third Rock Ventures, Nextech Invest, and Baker Bros. Advisors, the latter of which maintains a significant 4.9% stake as of February 2026. The Board of Directors features notable industry figures such as Lead Independent Director Alexis Borisy and former Moderna CFO Lorence Kim.